NMN vs NR in NAD+ research

Nicotinamide mononucleotide and nicotinamide riboside

NMN is nicotinamide mononucleotide; NR is nicotinamide riboside. NR becomes NMN before the body makes NAD+, while NMN enters one biochemical step closer. The review of NAD+ metabolic pathways describes how these starting materials feed synthesis.

One step closer sounds like an advantage. I distrust that shortcut as a way to choose a winner: the number of biochemical steps alone cannot establish which ingredient produces a useful human outcome.

A biochemical step describes a conversion. A comparison of clinical outcomes needs human trial data.

Research has concentrated on precursors because intact NAD+ is poorly taken up by cells. The skin-cell experiment on extracellular NAD illustrates processing outside human cells in culture; it supplies mechanistic context rather than a trial of swallowing NAD+.

NR: blood NAD+ and tolerability

In healthy overweight adults taking NR for 8 weeks, 100, 300, and 1000 mg/day raised whole-blood NAD+ by 22%, 51%, and 142%, respectively. The increase was maintained during the study, with no significant adverse-event differences from placebo.

It is an unusually tidy set of blood results. Those figures persuade me about the measured blood increase. A longer life would require evidence this experiment did not establish.

NMN trial outcomes

The 60-day trial in healthy middle-aged adults tested 300, 600, and 900 mg/day. All NMN groups had higher blood NAD+ at days 30 and 60, alongside improvements in walking distance and quality-of-life scores compared with placebo. No safety issues were reported.

The 10-week study of prediabetic postmenopausal women asked a different question at 250 mg/day. Muscle insulin sensitivity improved while body composition and HbA1c were unchanged. The narrower population and the particular outcome make this a useful result to examine closely.

That mixed muscle result seems worth a dedicated follow-up. A muscle response provides something concrete to investigate further.

Comparing the findings

These studies used different populations, durations and measurements. They do not establish a head-to-head winner between NMN and NR. The 2025 review of human NAD+ precursor trials found consistent blood increases alongside limited clinical efficacy and sparse tissue-specific evidence.

That pattern leaves room for worthwhile effects and considerable overstatement. I would judge a future comparison by the function it measures and the follow-up it provides.

NMN also carries a disputed FDA position on its eligibility as a dietary supplement. The regulatory account and safety findings describe that issue separately from the trial outcomes.